KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study

KRAS mutation is a confirmed predictive biomarker for anti-EGFR monoclonal antibody therapy response for metastatic colorectal cancer. However, its prognosis impact and the predictive potential for first-line standard chemotherapy remains unclear. On the other hand, V600E mutation is the most freque...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Carbonero, Nuria, Martinez-Useros, Javier, Li, Weiyao, Orta, Alberto, Perez, Nuria, Carames, Cristina, Hernandez, Tatiana, Moreno, Irene, Serrano, Gloria, Garcia-Foncillas, Jesus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016634/
https://www.ncbi.nlm.nih.gov/pubmed/31952366
http://dx.doi.org/10.3390/cells9010219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016634/
https://www.ncbi.nlm.nih.gov/pubmed/31952366
http://dx.doi.org/10.3390/cells9010219

Ejemplares similares